role of long-acting injectable second-generation antipsychotics in the treatment of first-episode schizophrenia a clinical perspective作用的长效注射第二代抗精神病药物治疗首发精神分裂症的临床的视角.pdfVIP

Hindawi Publishing Corporation Schizophrenia Research and Treatment Volume 2012, Article ID 764769, 7 pages doi:10.1155/2012/764769 Review Article Role of Long-Acting Injectable Second-Generation Antipsychotics in the Treatment of First-Episode Schizophrenia: A Clinical Perspective 1, 2 1, 2 2 1, 2 ˇ ˇ ˇ ´ ˇ ´ ´ ˇ ´ Radovan Prikryl, Hana Prikrylova Kucerova, Michaela Vrzalova, and Eva Ceskova 1 Central European Institute of Technology, Masaryk University (CEITEC-MU), Kamenice 753/5, 62500 Brno, Czech Republic 2 Department of Psychiatry, Faculty of Medicine Masaryk University, University Hospital Brno, Jihlavska 20, 62500 Brno, Czech Republic ˇ Correspondence should be addressed to Radovan Prikryl, radovan.prikryl@post.cz Received 24 October 2011; Revised 15 February 2012; Accepted 15 February 2012 Academic Editor: Dawn I. Velligan ˇ Copyright © 2012 Radovan Prikryl et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Approximately 80% of patients with the first-episode schizophrenia reach symptomatic remission after antipsychotic therapy. However, within two years most of them relapse,